Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519326 | 0.86 | KDM1A (0.41) | IRAK4AAK1 | |
| SCHEMBL4938339 | 0.84 | IRAK4 (0.46) | IRAK4NOS3NOS1NOS2 | |
| SCHEMBL4636443 | 0.81 | IRAK4 (0.47) | IRAK4 | |
| SCHEMBL13374903 | 0.81 | IRAK4 (0.35) | IRAK4NOS3NOS1NOS2EHMT2 | |
| SCHEMBL4635617 | 0.81 | IRAK4 (0.47) | IRAK4NOS3NOS1NOS2EHMT2 | |
| SCHEMBL4935780 | 0.81 | MAPT (0.49) | IRAK4 | |
| SCHEMBL3578860 | 0.80 | IRAK4 (0.35) | IRAK4EHMT2EHMT1 | |
| SCHEMBL4648772 | 0.79 | HTR4 (0.39) | IRAK4NOS3NOS1NOS2EHMT2 | |
| SCHEMBL17378320 | 0.79 | MAPT (0.46) | IRAK4NOS3NOS1NOS2AAK1 | |
| SCHEMBL1519578 | 0.78 | POLB (0.43) | NOS3NOS1NOS2EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8288413-B2 | Benzimidazolones which have activity at M1 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1937670-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036711-A1 | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306112-A1 | Benzimidazolones Which Have Activity at M1 Receptor | CHRM1, CHRM2, CHRM4 | IRAK4 2981/4885NOS3 1684/4885NOS1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.